You are here » Home » Companies » Company Overview » Lasa Supergenerics Ltd

Lasa Supergenerics Ltd.

BSE: 540702 Sector: Health care
NSE: LASA ISIN Code: INE670X01014
BSE 00:00 | 19 Aug 35.45 -0.45
(-1.25%)
OPEN

36.85

HIGH

37.30

LOW

35.20

NSE 00:00 | 19 Aug 35.25 -0.45
(-1.26%)
OPEN

36.35

HIGH

36.90

LOW

35.00

OPEN 36.85
PREVIOUS CLOSE 35.90
VOLUME 24068
52-Week high 85.05
52-Week low 25.40
P/E
Mkt Cap.(Rs cr) 144
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 36.85
CLOSE 35.90
VOLUME 24068
52-Week high 85.05
52-Week low 25.40
P/E
Mkt Cap.(Rs cr) 144
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Lasa Supergenerics Ltd. (LASA) - Company History

Lasa Supergenerics Limited was incorporated on March 11 2016. The Company is primarily engaged in the business of manufacturing trading producing processing preparing treating chemicals API Pharmaceuticals drugs etc. The Company is a vertically integrated group spanning the entire veterinary animal and human healthcare value chain-from discovery-to-delivery with established credentials in research manufacturing and global marketing. The Company is a veterinary API manufacturing entity which was acquired in April 2012. The manufacturing facility is located at Mahad & Chiplun in the Konkan region of Maharashtra. It specialises in `catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. To efficiently control the supply chain the Company is fully backward integrated for its key molecules-from discovery research up to full-scale bulk production. The Company's marketing footprint is entrenched across developing markets in multiple countries. Similarly the group expects to augment its export footprint significantly in width and depth in the future.The Company announced the launching of 2 new block buster products with all-time strong segment Oxycozanide. Oxyclozanide is an anthelmintic used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle especially buffalos in farm sheep and goats. For this the Company is setting up capacity in a brown field expansion at its Chiplun unit with a total capacity of 20 MT. It has got huge demand all over the globe as it is manufactured and have strong entry barriers. Likewise this product fits in product selection criteria through which the Company is confident of grabbing significant market share.Due to floods and fire in the company units the launch of another block buster product was deferred and commercialization of Oxyclozanide prolonged for some time to accommodate existing products in the company. The company received WHO Certificate of Good Manufacturing Practices from the Food and Drug Administration authorities for its manufacturing facility situated at Khed Ratnagiri.The Company has alliances with leading Indian and global animal health care conglomerates and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations. The Company is managed by a consortium of technocrats including its Chairman and Managing Director Mr. Omkar P. Herlekar who are impelled by passion and propelled by niche innovation. The leadership team which is guided by these values is well positioned to lead into the future.The Company is determined to achieve of becoming a leading force in the niche animal health care solutions. The objective on which it was founded have always inspired sustainable growth through innovation and shall continue to do so. Today the Company is the leading manufacturer player in veterinary APIs in India with a well-established brand known for its high-quality products amongst various customers.

.